BR112017012679A2 - compostos imunomoduladores, seus usos, composição e kit - Google Patents
compostos imunomoduladores, seus usos, composição e kitInfo
- Publication number
- BR112017012679A2 BR112017012679A2 BR112017012679A BR112017012679A BR112017012679A2 BR 112017012679 A2 BR112017012679 A2 BR 112017012679A2 BR 112017012679 A BR112017012679 A BR 112017012679A BR 112017012679 A BR112017012679 A BR 112017012679A BR 112017012679 A2 BR112017012679 A2 BR 112017012679A2
- Authority
- BR
- Brazil
- Prior art keywords
- kit
- composition
- immunomodulatory compounds
- protein
- amelioration
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000006916 protein interaction Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094008P | 2014-12-18 | 2014-12-18 | |
| PCT/US2015/065723 WO2016100285A1 (en) | 2014-12-18 | 2015-12-15 | Immunomodulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017012679A2 true BR112017012679A2 (pt) | 2018-03-06 |
Family
ID=55071200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017012679A BR112017012679A2 (pt) | 2014-12-18 | 2015-12-15 | compostos imunomoduladores, seus usos, composição e kit |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9861680B2 (enExample) |
| EP (1) | EP3233888B1 (enExample) |
| JP (1) | JP6625129B2 (enExample) |
| KR (1) | KR102602643B1 (enExample) |
| CN (1) | CN107108697B (enExample) |
| AR (1) | AR103093A1 (enExample) |
| AU (1) | AU2015362703A1 (enExample) |
| BR (1) | BR112017012679A2 (enExample) |
| CA (1) | CA2971189A1 (enExample) |
| EA (1) | EA033894B1 (enExample) |
| ES (1) | ES2940632T3 (enExample) |
| IL (1) | IL252853A0 (enExample) |
| MX (1) | MX2017007677A (enExample) |
| SG (1) | SG11201704823TA (enExample) |
| TW (1) | TW201629086A (enExample) |
| WO (1) | WO2016100285A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2666730C2 (ru) | 2012-12-07 | 2018-09-12 | Кемосентрикс, Инк. | Диазольные лактамы |
| MX380553B (es) | 2014-09-11 | 2025-03-12 | Bristol Myers Squibb Co | Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1. |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| PT3297438T (pt) | 2015-05-21 | 2022-01-25 | Chemocentryx Inc | Moduladores de ccr2 |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) * | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| BR112018070361A2 (pt) | 2016-04-07 | 2019-01-29 | Chemocentryx Inc | redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EA038019B1 (ru) | 2016-05-19 | 2021-06-23 | Бристол-Маерс Сквибб Компани | Иммуномодуляторы для пэт-визуализации |
| US11149066B2 (en) | 2016-09-13 | 2021-10-19 | Daiichi Sankyo Company, Limited | Thrombospondin 1-binding peptide |
| IL308894A (en) | 2016-10-14 | 2024-01-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| WO2018085750A2 (en) * | 2016-11-07 | 2018-05-11 | Bristol-Myers Squibb Company | Immunomodulators |
| KR20240023665A (ko) | 2016-12-23 | 2024-02-22 | 더 존스 홉킨스 유니버시티 | Pd-l1 발현에 기반한 종양 및 면역 세포 영상화 |
| WO2018232062A1 (en) * | 2017-06-15 | 2018-12-20 | University Of Washington | Macrocyclic polypeptides |
| US11066445B2 (en) * | 2017-06-23 | 2021-07-20 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of PD-1 |
| CN107602705B (zh) * | 2017-09-13 | 2018-08-31 | 北京鼎成肽源生物技术有限公司 | 一种基于蛋白互作用于检测细胞pd1表达情况的融合蛋白及其应用 |
| IL273188B2 (en) | 2017-09-25 | 2023-03-01 | Chemocentryx Inc | Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor |
| JP7257393B2 (ja) | 2017-10-03 | 2023-04-13 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤 |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| MA50423A (fr) | 2018-01-08 | 2020-08-26 | Chemocentryx Inc | Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2 |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| SG11202011651SA (en) | 2018-05-31 | 2020-12-30 | Ono Pharmaceutical Co | Biomarkers for determining the effectiveness of immune checkpoint inhibitors |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| TW202446772A (zh) | 2018-10-11 | 2024-12-01 | 日商小野藥品工業股份有限公司 | Ｓｔｉｎｇ促效化合物 |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| PL3873903T3 (pl) | 2018-10-31 | 2024-05-20 | Gilead Sciences, Inc. | Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1 |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| KR20210146348A (ko) | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| EP3946628A1 (en) | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020237081A1 (en) * | 2019-05-21 | 2020-11-26 | Bristol-Myers Squibb Company | Immunomodulators |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| JP7662156B2 (ja) | 2019-08-05 | 2025-04-15 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| AU2020350795A1 (en) | 2019-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Quantitative spatial profiling for LAG-3 antagonist therapy |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| EP4054723A1 (en) | 2019-11-08 | 2022-09-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
| EP4567109A3 (en) | 2019-12-06 | 2025-09-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| JP2023510737A (ja) * | 2020-01-06 | 2023-03-15 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤 |
| KR20220122751A (ko) * | 2020-01-06 | 2022-09-02 | 브리스톨-마이어스 스큅 컴퍼니 | 암 및 감염성 질환의 치료를 위한 pd-l1 억제제 및 면역조정제로서의 마크로시클릭 펩티드 |
| TW202421168A (zh) | 2020-03-20 | 2024-06-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
| KR20220161407A (ko) | 2020-03-30 | 2022-12-06 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | Method of cancer therapy |
| WO2021205631A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | Ｓｔｉｎｇ作動化合物 |
| CN113754736A (zh) * | 2020-06-02 | 2021-12-07 | 南京礼威生物医药有限公司 | 含酰肼结构的pd-l1环肽抑制剂 |
| EP4204095A1 (en) | 2020-08-28 | 2023-07-05 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| US20230381112A1 (en) | 2020-09-22 | 2023-11-30 | Vaccitech North America, Inc. | Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ |
| WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| EP4351564A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| CN118765285A (zh) | 2022-01-26 | 2024-10-11 | 百时美施贵宝公司 | 用于肝细胞癌的组合疗法 |
| US20230326022A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures |
| KR20250052397A (ko) | 2022-08-23 | 2025-04-18 | 오노 야꾸힝 고교 가부시키가이샤 | 이중 특이성 항체 |
| CN120731228A (zh) | 2022-12-21 | 2025-09-30 | 百时美施贵宝公司 | 肺癌的组合疗法 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| TW202504632A (zh) * | 2023-06-07 | 2025-02-01 | 日商肽夢想股份有限公司 | 靶向磷脂醯肌醇蛋白聚糖－３之肽組成物及其用途 |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2141175B1 (en) | 2007-03-26 | 2016-07-27 | The University of Tokyo | Process for synthesizing cyclic peptide compound |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
| EP2647720B1 (en) | 2010-12-03 | 2019-06-19 | The University of Tokyo | Peptide library production method, peptide library, and screening method |
| CN103732238A (zh) | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
| CN104159911A (zh) * | 2012-03-07 | 2014-11-19 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的模拟肽化合物 |
| JP2015512910A (ja) | 2012-03-29 | 2015-04-30 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | ヒトｐｄ１のｂｃループに由来する免疫調節性環状化合物 |
| WO2013182240A1 (en) | 2012-06-06 | 2013-12-12 | Polyphor Ag | Beta-hairpin peptidomimetics |
| EP2858667A1 (en) | 2012-06-06 | 2015-04-15 | Bionor Immuno AS | Hiv vaccine |
| JP2013253842A (ja) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法 |
| KR20150131269A (ko) | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| US9308236B2 (en) * | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| SG11201601685TA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | Cyclic peptidomimetic compounds as immunomodulators |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| MX380553B (es) | 2014-09-11 | 2025-03-12 | Bristol Myers Squibb Co | Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1. |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) * | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
-
2015
- 2015-12-14 US US14/967,960 patent/US9861680B2/en active Active
- 2015-12-15 MX MX2017007677A patent/MX2017007677A/es unknown
- 2015-12-15 SG SG11201704823TA patent/SG11201704823TA/en unknown
- 2015-12-15 JP JP2017532682A patent/JP6625129B2/ja active Active
- 2015-12-15 CN CN201580069483.3A patent/CN107108697B/zh active Active
- 2015-12-15 ES ES15820747T patent/ES2940632T3/es active Active
- 2015-12-15 CA CA2971189A patent/CA2971189A1/en not_active Abandoned
- 2015-12-15 AU AU2015362703A patent/AU2015362703A1/en not_active Abandoned
- 2015-12-15 EP EP15820747.2A patent/EP3233888B1/en active Active
- 2015-12-15 BR BR112017012679A patent/BR112017012679A2/pt not_active Application Discontinuation
- 2015-12-15 WO PCT/US2015/065723 patent/WO2016100285A1/en not_active Ceased
- 2015-12-15 EA EA201791231A patent/EA033894B1/ru not_active IP Right Cessation
- 2015-12-15 KR KR1020177019417A patent/KR102602643B1/ko active Active
- 2015-12-17 TW TW104142534A patent/TW201629086A/zh unknown
- 2015-12-17 AR ARP150104168A patent/AR103093A1/es unknown
-
2017
- 2017-06-12 IL IL252853A patent/IL252853A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170087518A (ko) | 2017-07-28 |
| JP2018504379A (ja) | 2018-02-15 |
| EP3233888B1 (en) | 2023-02-22 |
| JP6625129B2 (ja) | 2019-12-25 |
| US20160175386A1 (en) | 2016-06-23 |
| SG11201704823TA (en) | 2017-07-28 |
| CN107108697A (zh) | 2017-08-29 |
| MX2017007677A (es) | 2017-10-27 |
| CA2971189A1 (en) | 2016-06-23 |
| WO2016100285A1 (en) | 2016-06-23 |
| AR103093A1 (es) | 2017-04-12 |
| EA201791231A1 (ru) | 2018-01-31 |
| ES2940632T3 (es) | 2023-05-10 |
| US9861680B2 (en) | 2018-01-09 |
| IL252853A0 (en) | 2017-08-31 |
| AU2015362703A1 (en) | 2017-08-03 |
| EA033894B1 (ru) | 2019-12-06 |
| KR102602643B1 (ko) | 2023-11-16 |
| TW201629086A (zh) | 2016-08-16 |
| EP3233888A1 (en) | 2017-10-25 |
| CN107108697B (zh) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017012679A2 (pt) | compostos imunomoduladores, seus usos, composição e kit | |
| BR112017016039A2 (pt) | imunomoduladores. | |
| BR112017012704A2 (pt) | imunomoduladores | |
| BR112017019591A2 (pt) | imunomodulares | |
| CO2017004736A2 (es) | Péptidos macrociclicos útiles como inmunomoduladores | |
| BR112017003718A2 (pt) | inibidores macrocíclicos das interações de proteína/proteína de pd-1/pd-l1 e cd80(b7-1)/pd-l1 | |
| BR112018017114A2 (pt) | imunomoduladores | |
| MX2017004542A (es) | Inmunomoduladores. | |
| UY37194A (es) | Inmunomoduladores | |
| PH12015502027A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1) / pd-l1 protein / protein interactions | |
| MX375352B (es) | Reguladores de nrf2. | |
| CL2017001661A1 (es) | Compuestos biciclicos fusionados para el tratamiento de una enfermedad. | |
| MX2017002469A (es) | Composiciones de matrices extracelulares. | |
| BR112017027721A2 (pt) | formulação de alta concentração | |
| BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2017003949A (es) | Derivados peptidicos novedosos y sus usos. | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| BR112017010627A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |